Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis

Background Increased platelet activity in type 2 diabetes mellitus (T2DM) plays a key role in the development of vascular complications. Platelet indices such as mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell ratio (PLCR), and plateletcrit (PCT) reflect both the f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2024-10, Vol.16 (10), p.e71796
Hauptverfasser: Sengupta, Piyali, Priyadarshini, Aparajita, Kumar Behera, Pradip, Padarabinda Tripathy, Krishna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page e71796
container_title Curēus (Palo Alto, CA)
container_volume 16
creator Sengupta, Piyali
Priyadarshini, Aparajita
Kumar Behera, Pradip
Padarabinda Tripathy, Krishna
description Background Increased platelet activity in type 2 diabetes mellitus (T2DM) plays a key role in the development of vascular complications. Platelet indices such as mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell ratio (PLCR), and plateletcrit (PCT) reflect both the functional and morphological status of platelets. These indices are markers of inflammation and metabolic dysregulation, which are pivotal in diabetic vasculopathy. If platelet indices correlate with nephropathy severity, they could be used as cost-effective, accessible markers for assessing disease progression in T2DM. Materials and methods This cross-sectional study was conducted at Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, India, from September 2019 to August 2021. A total of 203 patients with T2DM and nephropathy were included, diagnosed per American Diabetes Association 2017 criteria and staged using Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Nephropathy was assessed using the albumin-to-creatinine ratio, and the glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Venous blood samples were collected to measure platelet indices using the SYSMEX XN-1000 automated analyzer (Sysmex Corporation, Kobe, Japan). Statistical analysis was conducted using Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 24.0, Armonk, NY), with a comparison of MPV, PDW, PCT, and PLCR across nephropathy stages performed via the Kruskal-Wallis test. Pairwise comparisons were made using the Mann-Whitney test, with a significance level set at p < 0.05. Results The study population had a mean age of 61.7 ± 12.0 years, with 62.1% over 60 years and a male-to-female ratio of 1.5:1. The average diabetes duration was 8.0 ± 5.2 years. The mean platelet count was 236.4 ± 112.6, and the mean values for MPV, PDW, PCT, and PLCR were 11.4 ± 1.7, 15.2 ± 3.8, 0.28 ± 0.11, and 38.9 ± 11.8, respectively. Most patients (63.1%) were in the early stages of nephropathy (stages 1-3). Significant differences in platelet indices were observed across nephropathy stages, with Kruskal-Wallis p-values of 0.027, 0.009, 0.001, and 0.007 for MPV, PDW, PCT, and PLCR, respectively. Pairwise comparisons showed that platelet indices were significantly elevated in advanced nephropathy stages (stages 4 and 5) compared to early stages (stages 1 and 2) with p < 0.05. Conclusion There is
doi_str_mv 10.7759/cureus.71796
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11569825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3134433234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1775-6982a27a1ee7d8ecf32ef2f7b017e0dcf8bce1f60c5ede314bd9d6ff26757d4e3</originalsourceid><addsrcrecordid>eNpdkU9P3DAQxa2qqCDKrefKUi89NNR_kjjppdpuaUGiLRL0bDnOmDXyxsF2UPMJ-Np4WUDQi2ck__zGbx5C7yg5FKJqP-spwBQPBRVt_QrtMVo3RUOb8vWzfhcdxHhFCKFEMCLIG7TL26rihNM9dHv0b3Q-2OESnzmVwEHCJ0NvNUSsIj4LkPvkQ8Te4N8wroIfVVrN-BxuINg0Yzvgi3kEzPB3qzpI-eEvcM6mKX7BC3zs42iTcsU3FaHHy-BjLM5BJ-sH5fAiH3O08S3aMcpFOHio--jvj6OL5XFx-ufnyXJxWmiaDRd12zDFhKIAom9AG87AMCM6QgWQXpum00BNTXQFPXBadn3b18awWlSiL4Hvo69b3XHq1tBrGFJQTo7BrlWYpVdWvrwZ7Epe-htJabUZXmWFjw8KwV9PEJNc26izYzWAn6LklLV1Q5kgGf3wH3rlp5AdbyhelpwzXmbq05bSm90EME-_oURuUpbblOV9yhl__9zBE_yYKb8Dl-mm7Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134433234</pqid></control><display><type>article</type><title>Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Sengupta, Piyali ; Priyadarshini, Aparajita ; Kumar Behera, Pradip ; Padarabinda Tripathy, Krishna</creator><creatorcontrib>Sengupta, Piyali ; Priyadarshini, Aparajita ; Kumar Behera, Pradip ; Padarabinda Tripathy, Krishna</creatorcontrib><description>Background Increased platelet activity in type 2 diabetes mellitus (T2DM) plays a key role in the development of vascular complications. Platelet indices such as mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell ratio (PLCR), and plateletcrit (PCT) reflect both the functional and morphological status of platelets. These indices are markers of inflammation and metabolic dysregulation, which are pivotal in diabetic vasculopathy. If platelet indices correlate with nephropathy severity, they could be used as cost-effective, accessible markers for assessing disease progression in T2DM. Materials and methods This cross-sectional study was conducted at Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, India, from September 2019 to August 2021. A total of 203 patients with T2DM and nephropathy were included, diagnosed per American Diabetes Association 2017 criteria and staged using Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Nephropathy was assessed using the albumin-to-creatinine ratio, and the glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Venous blood samples were collected to measure platelet indices using the SYSMEX XN-1000 automated analyzer (Sysmex Corporation, Kobe, Japan). Statistical analysis was conducted using Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 24.0, Armonk, NY), with a comparison of MPV, PDW, PCT, and PLCR across nephropathy stages performed via the Kruskal-Wallis test. Pairwise comparisons were made using the Mann-Whitney test, with a significance level set at p &lt; 0.05. Results The study population had a mean age of 61.7 ± 12.0 years, with 62.1% over 60 years and a male-to-female ratio of 1.5:1. The average diabetes duration was 8.0 ± 5.2 years. The mean platelet count was 236.4 ± 112.6, and the mean values for MPV, PDW, PCT, and PLCR were 11.4 ± 1.7, 15.2 ± 3.8, 0.28 ± 0.11, and 38.9 ± 11.8, respectively. Most patients (63.1%) were in the early stages of nephropathy (stages 1-3). Significant differences in platelet indices were observed across nephropathy stages, with Kruskal-Wallis p-values of 0.027, 0.009, 0.001, and 0.007 for MPV, PDW, PCT, and PLCR, respectively. Pairwise comparisons showed that platelet indices were significantly elevated in advanced nephropathy stages (stages 4 and 5) compared to early stages (stages 1 and 2) with p &lt; 0.05. Conclusion There is a significant correlation between platelet indices and the severity of nephropathy in T2DM patients. MPV, PDW, PCT, and PLCR all increase in advanced stages of nephropathy, suggesting these indices can be used as surrogate markers for assessing disease progression. Their ease of measurement and cost-effectiveness make them valuable tools in monitoring diabetic nephropathy, offering a simpler and more cost-effective alternative for monitoring disease progression.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.71796</identifier><identifier>PMID: 39553031</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Atherosclerosis ; Blood platelets ; Blood tests ; Chronic illnesses ; Diabetes ; Diabetic nephropathy ; Endocrinology/Diabetes/Metabolism ; Females ; Hemoglobin ; Hospitals ; Hyperglycemia ; Hypertension ; Internal Medicine ; Kidney diseases ; Metabolism ; Morbidity ; Mortality ; Nephrology ; Population</subject><ispartof>Curēus (Palo Alto, CA), 2024-10, Vol.16 (10), p.e71796</ispartof><rights>Copyright © 2024, Sengupta et al.</rights><rights>Copyright © 2024, Sengupta et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Sengupta et al. 2024 Sengupta et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1775-6982a27a1ee7d8ecf32ef2f7b017e0dcf8bce1f60c5ede314bd9d6ff26757d4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569825/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569825/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39553031$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sengupta, Piyali</creatorcontrib><creatorcontrib>Priyadarshini, Aparajita</creatorcontrib><creatorcontrib>Kumar Behera, Pradip</creatorcontrib><creatorcontrib>Padarabinda Tripathy, Krishna</creatorcontrib><title>Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Background Increased platelet activity in type 2 diabetes mellitus (T2DM) plays a key role in the development of vascular complications. Platelet indices such as mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell ratio (PLCR), and plateletcrit (PCT) reflect both the functional and morphological status of platelets. These indices are markers of inflammation and metabolic dysregulation, which are pivotal in diabetic vasculopathy. If platelet indices correlate with nephropathy severity, they could be used as cost-effective, accessible markers for assessing disease progression in T2DM. Materials and methods This cross-sectional study was conducted at Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, India, from September 2019 to August 2021. A total of 203 patients with T2DM and nephropathy were included, diagnosed per American Diabetes Association 2017 criteria and staged using Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Nephropathy was assessed using the albumin-to-creatinine ratio, and the glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Venous blood samples were collected to measure platelet indices using the SYSMEX XN-1000 automated analyzer (Sysmex Corporation, Kobe, Japan). Statistical analysis was conducted using Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 24.0, Armonk, NY), with a comparison of MPV, PDW, PCT, and PLCR across nephropathy stages performed via the Kruskal-Wallis test. Pairwise comparisons were made using the Mann-Whitney test, with a significance level set at p &lt; 0.05. Results The study population had a mean age of 61.7 ± 12.0 years, with 62.1% over 60 years and a male-to-female ratio of 1.5:1. The average diabetes duration was 8.0 ± 5.2 years. The mean platelet count was 236.4 ± 112.6, and the mean values for MPV, PDW, PCT, and PLCR were 11.4 ± 1.7, 15.2 ± 3.8, 0.28 ± 0.11, and 38.9 ± 11.8, respectively. Most patients (63.1%) were in the early stages of nephropathy (stages 1-3). Significant differences in platelet indices were observed across nephropathy stages, with Kruskal-Wallis p-values of 0.027, 0.009, 0.001, and 0.007 for MPV, PDW, PCT, and PLCR, respectively. Pairwise comparisons showed that platelet indices were significantly elevated in advanced nephropathy stages (stages 4 and 5) compared to early stages (stages 1 and 2) with p &lt; 0.05. Conclusion There is a significant correlation between platelet indices and the severity of nephropathy in T2DM patients. MPV, PDW, PCT, and PLCR all increase in advanced stages of nephropathy, suggesting these indices can be used as surrogate markers for assessing disease progression. Their ease of measurement and cost-effectiveness make them valuable tools in monitoring diabetic nephropathy, offering a simpler and more cost-effective alternative for monitoring disease progression.</description><subject>Atherosclerosis</subject><subject>Blood platelets</subject><subject>Blood tests</subject><subject>Chronic illnesses</subject><subject>Diabetes</subject><subject>Diabetic nephropathy</subject><subject>Endocrinology/Diabetes/Metabolism</subject><subject>Females</subject><subject>Hemoglobin</subject><subject>Hospitals</subject><subject>Hyperglycemia</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Metabolism</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Nephrology</subject><subject>Population</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU9P3DAQxa2qqCDKrefKUi89NNR_kjjppdpuaUGiLRL0bDnOmDXyxsF2UPMJ-Np4WUDQi2ck__zGbx5C7yg5FKJqP-spwBQPBRVt_QrtMVo3RUOb8vWzfhcdxHhFCKFEMCLIG7TL26rihNM9dHv0b3Q-2OESnzmVwEHCJ0NvNUSsIj4LkPvkQ8Te4N8wroIfVVrN-BxuINg0Yzvgi3kEzPB3qzpI-eEvcM6mKX7BC3zs42iTcsU3FaHHy-BjLM5BJ-sH5fAiH3O08S3aMcpFOHio--jvj6OL5XFx-ufnyXJxWmiaDRd12zDFhKIAom9AG87AMCM6QgWQXpum00BNTXQFPXBadn3b18awWlSiL4Hvo69b3XHq1tBrGFJQTo7BrlWYpVdWvrwZ7Epe-htJabUZXmWFjw8KwV9PEJNc26izYzWAn6LklLV1Q5kgGf3wH3rlp5AdbyhelpwzXmbq05bSm90EME-_oURuUpbblOV9yhl__9zBE_yYKb8Dl-mm7Q</recordid><startdate>20241018</startdate><enddate>20241018</enddate><creator>Sengupta, Piyali</creator><creator>Priyadarshini, Aparajita</creator><creator>Kumar Behera, Pradip</creator><creator>Padarabinda Tripathy, Krishna</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241018</creationdate><title>Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis</title><author>Sengupta, Piyali ; Priyadarshini, Aparajita ; Kumar Behera, Pradip ; Padarabinda Tripathy, Krishna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1775-6982a27a1ee7d8ecf32ef2f7b017e0dcf8bce1f60c5ede314bd9d6ff26757d4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Atherosclerosis</topic><topic>Blood platelets</topic><topic>Blood tests</topic><topic>Chronic illnesses</topic><topic>Diabetes</topic><topic>Diabetic nephropathy</topic><topic>Endocrinology/Diabetes/Metabolism</topic><topic>Females</topic><topic>Hemoglobin</topic><topic>Hospitals</topic><topic>Hyperglycemia</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Metabolism</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Nephrology</topic><topic>Population</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sengupta, Piyali</creatorcontrib><creatorcontrib>Priyadarshini, Aparajita</creatorcontrib><creatorcontrib>Kumar Behera, Pradip</creatorcontrib><creatorcontrib>Padarabinda Tripathy, Krishna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sengupta, Piyali</au><au>Priyadarshini, Aparajita</au><au>Kumar Behera, Pradip</au><au>Padarabinda Tripathy, Krishna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-10-18</date><risdate>2024</risdate><volume>16</volume><issue>10</issue><spage>e71796</spage><pages>e71796-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Background Increased platelet activity in type 2 diabetes mellitus (T2DM) plays a key role in the development of vascular complications. Platelet indices such as mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell ratio (PLCR), and plateletcrit (PCT) reflect both the functional and morphological status of platelets. These indices are markers of inflammation and metabolic dysregulation, which are pivotal in diabetic vasculopathy. If platelet indices correlate with nephropathy severity, they could be used as cost-effective, accessible markers for assessing disease progression in T2DM. Materials and methods This cross-sectional study was conducted at Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, India, from September 2019 to August 2021. A total of 203 patients with T2DM and nephropathy were included, diagnosed per American Diabetes Association 2017 criteria and staged using Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Nephropathy was assessed using the albumin-to-creatinine ratio, and the glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Venous blood samples were collected to measure platelet indices using the SYSMEX XN-1000 automated analyzer (Sysmex Corporation, Kobe, Japan). Statistical analysis was conducted using Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 24.0, Armonk, NY), with a comparison of MPV, PDW, PCT, and PLCR across nephropathy stages performed via the Kruskal-Wallis test. Pairwise comparisons were made using the Mann-Whitney test, with a significance level set at p &lt; 0.05. Results The study population had a mean age of 61.7 ± 12.0 years, with 62.1% over 60 years and a male-to-female ratio of 1.5:1. The average diabetes duration was 8.0 ± 5.2 years. The mean platelet count was 236.4 ± 112.6, and the mean values for MPV, PDW, PCT, and PLCR were 11.4 ± 1.7, 15.2 ± 3.8, 0.28 ± 0.11, and 38.9 ± 11.8, respectively. Most patients (63.1%) were in the early stages of nephropathy (stages 1-3). Significant differences in platelet indices were observed across nephropathy stages, with Kruskal-Wallis p-values of 0.027, 0.009, 0.001, and 0.007 for MPV, PDW, PCT, and PLCR, respectively. Pairwise comparisons showed that platelet indices were significantly elevated in advanced nephropathy stages (stages 4 and 5) compared to early stages (stages 1 and 2) with p &lt; 0.05. Conclusion There is a significant correlation between platelet indices and the severity of nephropathy in T2DM patients. MPV, PDW, PCT, and PLCR all increase in advanced stages of nephropathy, suggesting these indices can be used as surrogate markers for assessing disease progression. Their ease of measurement and cost-effectiveness make them valuable tools in monitoring diabetic nephropathy, offering a simpler and more cost-effective alternative for monitoring disease progression.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>39553031</pmid><doi>10.7759/cureus.71796</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2024-10, Vol.16 (10), p.e71796
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11569825
source PubMed Central Open Access; PubMed Central
subjects Atherosclerosis
Blood platelets
Blood tests
Chronic illnesses
Diabetes
Diabetic nephropathy
Endocrinology/Diabetes/Metabolism
Females
Hemoglobin
Hospitals
Hyperglycemia
Hypertension
Internal Medicine
Kidney diseases
Metabolism
Morbidity
Mortality
Nephrology
Population
title Exploring Platelet Indices as Predictors of Nephropathy Severity in Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A37%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20Platelet%20Indices%20as%20Predictors%20of%20Nephropathy%20Severity%20in%20Type%202%20Diabetes%20Mellitus:%20A%20Hospital-Based%20Cross-Sectional%20Analysis&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Sengupta,%20Piyali&rft.date=2024-10-18&rft.volume=16&rft.issue=10&rft.spage=e71796&rft.pages=e71796-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.71796&rft_dat=%3Cproquest_pubme%3E3134433234%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134433234&rft_id=info:pmid/39553031&rfr_iscdi=true